Peritoneal accumulation of age and peritoneal membrane permeability

Peritoneal Dialysis International

Volumn 20, Issue 4, 2000, Pages 452-460

  Park, M S ^a   Lee, H A ^a   Chu, W S ^a   Yang, D H ^a   Hwang, S D ^a  

^a Hyonam Kidney Laboratory   (South Korea)

Author keywords

Advanced glycosylation end products; AGE; Peritoneal permeability; Peritonitis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CREATININE; DIALYSIS FLUID; GLUCOSE; HYDROXYPROLINE; POLYCLONAL ANTIBODY; SODIUM;

ADULT; AGE; AGED; ARTICLE; CATHETERIZATION; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL BIOPSY; GLYCOSYLATION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LONG TERM CARE; MALE; MEMBRANE PERMEABILITY; PERITONEAL CAVITY; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; ULTRAFILTRATION; WOUND INFECTION;

EID: 0033790382     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002000413     Document Type: Article

References (39)

1. Peritoneal membrane function after 5 years of CAPD
2. A prospective study of peritoneal transport in CAPD patients
3. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis
4. Changes in peritoneal membrane transport rates in patients on long term CAPD
5. Peritoneal solute clearances after four years of continuous ambulatory peritoneal dialysis
6. How long is continuous peritoneal dialysis possible? Results of a prospective medium longterm study
7. Symptomatic fluid retention in patients on continuous peritoneal dialysis
8. Morphology of the peritoneum in CAPD
9. Monitoring peritoneal histopathology in peritoneal dialysis: The role of biopsy registry
10. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vitro model for the study of diabetic microangiopathy
11. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: Ultrastructural changes of reduplicated peritoneal basement membrane
12. New evidence on the pathogenesis of sclerosing encapsulating peritonitis (SEP) obtained from serial biopsies
13. Microcirculation and diabetes
14. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis
15. The Wisconsin epidemiologic study of diabetic nephropathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years
16. Retinopathy in older type II diabetics: Association with glucose control
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
18. Nonenzymatic glycosylation and the pathogenesis of diabetic complications
19. Exogeneous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
20. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
21. Serum advanced glycosylation end products: A new class of uremic toxin?
22. Serum advanced glycosylation end-products in patients in hemodialysis and CAPD
23. Advanced glycation end products in continuous ambulatory peritoneal dialysis patients
24. Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis
25. Clearance of pentosidine, an advanced glycosylation end product, by different modalities of renal replacement therapy
26. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure
27. Immunohistochemical detection of advanced glycation end products (AGEs) in the peritoneum and its possible pathophysiological role in CAPD
28. Analysis of non enzymatic glycosylation in vivo: Impact of different dialysis solutions
29. Peritoneal equilibration test
30. Nonenzymatic glycosylation and glucose-dependent cross-linking of protein
31. Immunohistochemical detection of advanced glycosylation end products in vivo
32. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure
33. Antioxidant status in experimental peritonitis: Effects of alpha tocopherol and taurolin
34. Increased collagen-linked pentosidine levels and advanced glycosylation end-products in early diabetic nephropathy
35. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging
36. Advanced glycosylation end products in patients with diabetic nephropathy
37. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects
38. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia
39. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine